There are currently 126 active clinical trials seeking participants for Major Depressive Disorder research studies. The states with the highest number of trials for Major Depressive Disorder participants are California, Florida, Texas and New York.
PD, PK, and Safety of ALTO-203 in Patients With MDD
NCT06391593
Recruiting
The goal of this clinical trial is to determine the pharmacodynamic effects of ALTO-203 in patients with MDD in a randomized, placebo-controlled, single-dose crossover treatment period. Additionally, safety, tolerability, and PK will be assessed in a subsequent randomized placebo-controlled multi-dose parallel-group treatment period of 28 days. Participants will complete subjective response questionnaires and perform cognitive tasks during the single-dose period, in which participants will rece... Read More
Gender:
ALL
Ages:
Between 25 years and 64 years
Trial Updated:
08/05/2024
Locations: Site 4058, Tucson, Arizona +14 locations
Conditions: Major Depressive Disorder, Anhedonia
Register for Updates
Using Electrophysiology to Index Non-invasive Brain Stimulation Effects on Reward System Functioning in Depression
NCT05194098
Recruiting
Depression is a leading cause of morbidity and mortality, conferring substantial healthcare and societal costs. By studying methods to non-invasively target neural circuitry involved in reward responsivity, information generated by this project will improve understanding of the circuit alterations that underlie motivation and pleasure deficits in depression, and could also lead to the development of biologically-based markers of neurostimulation-based treatment response.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/31/2024
Locations: San Francisco VA Medical Center, San Francisco, California
Conditions: Major Depressive Disorder
Register for Updates
Reward Processing and Depressive Subtypes: Identifying Neural Biotypes
NCT06080646
Recruiting
Deficits in motivation and pleasure are common in depression, and thought to be caused by alterations in the ways in which the brain anticipates, evaluates, and adaptively uses reward-related information. However, reward processing is a complex, multi-circuit phenomenon, and the precise neural mechanisms that contribute to the absence or reduction of pleasure and motivation are not well understood. Variation in the clinical presentation of depression has long been a rule rather than an exception... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/31/2024
Locations: San Francisco Healthcare System, San Francisco, California
Conditions: Depression, Depressive Disorder, Major Depressive Disorder, Major Depressive Episode, Depressive Symptoms, Anhedonia
Register for Updates
Low Amplitude Pulse Seizure Therapy Versus Standard Ultra-Brief Right Unilateral Electroconvulsive Therapy
NCT06529029
Recruiting
This protocol proposes an initial randomized clinical trial that includes all patients with suicidal ideation (SI) at baseline, and with SI as the primary outcome measure to examine whether Right Unilateral Low-Amplitude Pulse - Seizure Therapy (RUL LAP-ST) treatment has more magnitude and rate of remission of SI as conventional pulse amplitude Right Unilateral Electroconvulsive Therapy (RUL ECT) (based on our prior secondary analysis). Our central hypothesis is that RUL LAP-ST has significantly... Read More
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
07/30/2024
Locations: Pine Rest Christian Mental Health Services, Grand Rapids, Michigan
Conditions: Suicidal Ideation, Major Depressive Disorder, Schizo Affective Disorder, Bipolar Disorder
Register for Updates
Decoding and Modulating Affective Brain States
NCT05437705
Recruiting
Generating personalized brain signatures of negative emotion along with personalized brain stimulation protocols to disrupt these patterns. We plan to use fMRI and muscle activity data to determine negative affect maps for each participant. We will then try a variety of patterned repetitive transcranial magnetic stimulation sequences while recording fMRI which will be the basis of two sessions of 3-day individualized brain stimulation designed to reduce negative affect.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/19/2024
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Rumination, Major Depressive Disorder, Anxiety
Register for Updates
Study of ALTO-300 in MDD
NCT05922878
Recruiting
The purpose of this study is to determine efficacy differences between ALTO-300 and placebo, used adjunctively to an antidepressant, related to patient characteristics.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/05/2024
Locations: Site 200, Phoenix, Arizona +43 locations
Conditions: Major Depressive Disorder
Register for Updates
5-HTP and Creatine for Depression R33 Phase
NCT05895747
Recruiting
This is a three-armed clinical trial examining the effect of 5-hydroxytryptophan and creatine monohydrate as augmenting agents for the treatment of depression. Subjects will be randomized between 5-HTP 100mg BID + creatine 5g daily, 5-HTP 200mg BID + creatine 10g daily, vs double placebo, for 8 weeks. The ability of the interventions to affect biomarkers associated with depression will be assessed using brain phosphorus magnetic resonance spectroscopy, functional connectivity imaging, and plasma... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/01/2024
Locations: University of Utah Department of Psychiatry, Salt Lake City, Utah
Conditions: Major Depressive Disorder
Register for Updates
Mechanisms of Rumination Change in Adolescent Depression
NCT03859297
Recruiting
This study will evaluate whether a newer treatment, rumination-focused cognitive behavioral treatment, which includes mindfulness and can be used to reduce ruminative habits, change ways in which key brain regions interact with each other (e.g.., often called connectivity), and whether these changes in habits and brain connectivity can reduce the risk for recurrence of depression in the next two years.
Gender:
ALL
Ages:
Between 14 years and 17 years
Trial Updated:
06/25/2024
Locations: Nationwide Children's Hospital, Columbus, Ohio +2 locations
Conditions: Major Depressive Disorder, Mood Disorders
Register for Updates
Gamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant Depression
NCT06480201
Recruiting
The core objective of this study is to enhance the translational potential of this electroencephalogram (EEG) biomarker by using ketamine(KET)-induced gamma potentiation as a prognostic marker of 4-week treatment outcome. Previous research focused exclusively on KET-induced gamma band potentiation (GBP) in the context of a single infusion. Our study design captures the clinical variation associated with real-world treatment resistant depression (TRD) patients and allows us to analyze the relativ... Read More
Gender:
ALL
Ages:
Between 21 years and 45 years
Trial Updated:
06/24/2024
Locations: Wells Medicine, Houston, Texas +1 locations
Conditions: Healthy, Major Depressive Disorder, Treatment Resistant Depression
Register for Updates
Mindfulness Engaged Neurostimulation for Depression
NCT06399406
Recruiting
Repetitive Transcranial Magnetic stimulation (rTMS) is an FDA-approved therapy for treatment resistant depression (TRD) that involves brief magnetic stimulation pulses on the dorsolateral prefrontal cortex (DLPFC) brain region. But studies of rTMS alone show remission rates of \~30%. Additionally, rTMS has not been shown to improve cognitive functioning that may be an independent factor predicting treatment success. This study will develop a novel multimodal treatment, which combines intermitten... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/20/2024
Locations: University of California San Diego, La Jolla, California
Conditions: Depression, Treatment Resistant Depression, Major Depressive Disorder, Depressive Disorder
Register for Updates
Predicting SSRI Efficacy in Veterans With PTSD
NCT04183205
Recruiting
This is a research study to examine the effectiveness of a brief screening method that may predict which people with posttraumatic stress disorder (PTSD) or depression are most likely to show a positive response to selective serotonin reuptake inhibitor (SSRI) medications. Participants will be recruited over approximately 5.25 years, until at least 94 participants complete the 17 week study.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/17/2024
Locations: VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston, Massachusetts +1 locations
Conditions: Posttraumatic Stress Disorder, Major Depressive Disorder
Register for Updates
Neuroactive Steroid to Treat Depressed Mood: A Trial for People With HIV
NCT05570812
Recruiting
This study will determine the effects of pregnenolone on brain function, inflammation and depressive symptoms in people with HIV who have depression. Participants in this study will receive a pill of either pregnenolone or placebo, and can stay on their current antidepression medications. Brain imaging and behavioral assessments will be performed during the study.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
06/07/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Major Depressive Disorder, Anxiety Depression, Hiv
Register for Updates